Compare Exelixis Inc. Common Stock (EXEL) vs Ermenegildo Zegna N.V. Ordinary Shares (ZGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Exelixis Inc. Common Stock vs Ermenegildo Zegna N.V. Ordinary Shares — how do they compare? Exelixis Inc. Common Stock trades at $61.44 (market cap $15.12B), while Ermenegildo Zegna N.V. Ordinary Shares trades at $12.8 (market cap $3.44B). The key difference: Exelixis Inc. Common Stock is far larger — about 4.4× Ermenegildo Zegna N.V. Ordinary Shares's market cap, and Ermenegildo Zegna N.V. Ordinary Shares pays a 1.07% dividend while Exelixis Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Exelixis Inc. Common Stock for 3 Days and Ermenegildo Zegna N.V. Ordinary Shares for 0 Days on average.
| EXEL | ZGN | |
|---|---|---|
Market Cap | $15.12B | $3.44B |
Volume | 2,752,905 | 781,107 |
Sector | Health | Consumer Cyclical |
52-Week High | $60.99 | $15.25 |
52-Week Low | $34.54 | $8.69 |
Typical Hold Time | 3 Days | 0 Days |
Enterprise Value | $14.44B | $4.40B |
Dividend Yield | — | 1.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EXEL trades at $59.51, down 0.52% on the day but near its 52-week high of $61.66 reached on October 12, 2026. The stock shows strong technical momentum with bullish moving averages and has consistently beaten earnings estimates in recent quarters. Recent news highlights include a three-month FDA review delay for zanzalintinib but continued growth in CABOMETYX revenue, which surpassed $3 billion annually.
The outlook remains positive with strong profitability metrics (35.33% net margin, 44.39% ROE) and projected revenue growth to $2.4 billion in 2026. Key risks include regulatory delays for new drug approvals and competitive pressures in oncology. Analyst consensus is mixed with 48% buy ratings but a price target of $52.33 suggesting potential downside from current levels.
ZGN trades at $12.94, up 2.7% with a neutral technical outlook. The stock shows mixed fundamentals with a high P/E of 38.5 but strong gross margins of 67.58%. Recent earnings beat expectations in three of the last four quarters, though Q2 2026 missed estimates. Analyst consensus is bullish with a $14.12 price target and 66.7% buy ratings. Revenue growth continues with 2025 reaching $1.92B, though net margins compressed to 3.98%.
ZGN presents a growth opportunity with expanding DTC momentum and margin potential, but faces valuation concerns and competitive pressures. The stock's upside depends on sustained earnings growth and successful execution of the retail-first strategy amidst fashion sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Exelixis Inc. Common Stock
Exelixis develops and commercializes medicines for cancer. Its research focuses on targeted therapies for oncology.
Read more on EXEL →About Ermenegildo Zegna N.V. Ordinary Shares
Ermenegildo Zegna N.V. is a luxury fashion group whose brands include Zegna, Thom Browne, and Tom Ford Fashion. The company operates a vertically integrated supply chain, sourcing wool from its own Australian farm through to finished garment production.
Read more on ZGN →
